Oppenheimer Asset Management Inc. Buys 133 Shares of Atrion Co. (NASDAQ:ATRI)

Oppenheimer Asset Management Inc. lifted its stake in shares of Atrion Co. (NASDAQ:ATRI) by 12.0% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,238 shares of the medical instruments supplier’s stock after acquiring an additional 133 shares during the quarter. Oppenheimer Asset Management Inc. owned approximately 0.07% of Atrion worth $560,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Jump Financial LLC purchased a new position in Atrion during the 4th quarter worth $234,000. Quadrant Capital Group LLC bought a new position in shares of Atrion during the 4th quarter worth $36,000. Penn Mutual Asset Management LLC bought a new position in shares of Atrion during the 4th quarter worth $1,949,000. Principal Financial Group Inc. purchased a new position in shares of Atrion during the first quarter valued at $280,000. Finally, BNP Paribas Financial Markets raised its holdings in shares of Atrion by 3.6% in the first quarter. BNP Paribas Financial Markets now owns 723 shares of the medical instruments supplier’s stock valued at $335,000 after acquiring an additional 25 shares in the last quarter. Institutional investors own 66.19% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on shares of Atrion in a report on Thursday. They set a “sell” rating on the stock.

Atrion Price Performance

Shares of ATRI stock opened at $459.92 on Friday. The firm has a market cap of $809.46 million, a price-to-earnings ratio of 43.23 and a beta of 0.69. Atrion Co. has a 52-week low of $274.98 and a 52-week high of $503.24. The company’s 50 day moving average is $458.90 and its 200 day moving average is $444.77.

Atrion (NASDAQ:ATRI) last announced its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported $0.23 earnings per share (EPS) for the quarter. The business had revenue of $48.77 million for the quarter. Atrion had a return on equity of 7.75% and a net margin of 10.60%.

About Atrion

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.